A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Phase 1 Recruiting 232 enrolled SparX Biotech(Jiangsu) Co., Ltd.

Non-randomizedSequentialOpen-labelTreatment

Summary

Part 1 of this study is an open-label, dose-escalation, and safety expansion study of an anti-LILRB2 / anti-PD-L1 bispecific antibody SPX- 303 in patients with solid tumors. Part 2 of this study is an indication-specific dose expansion study of SPX-303.

Timeline

Start: 2024-03-20
Primary completion: 2027-09
Completion: 2027-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SPX-303	Unknown	—	Intravenous

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

Summary

Timeline

Drugs

Indications